FILING ANALYSIS · TUESDAY, NOVEMBER 3
Contineum Therapeutics, Inc. CTNM — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $18.7 million for the third quarter of 2026 and has a projected cash runway that extends through mid-2029, with no quantified surprises in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →